Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

被引：0
|
作者：
Bruemmendorf, T. [1 ]
Guigay, J. [2 ]
Mesia, R. [3 ]
Trigo, J. [4 ]
Keilholz, U. [5 ]
Dittrich, C. [6 ,7 ]
Kerber, A. [8 ]
Picard, M. [8 ]
Vermorken, J. [9 ]
机构：
[1] UCCH, Univ Med Ctr Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Inst Gustave Roussy, Villejuif, France
[3] Inst Catala Oncol Hosp, Barcelona, Spain
[4] Hosp Univ Virgen Victoria, Malaga, Spain
[5] Hematol & Med Oncol CBF, Charite, Berlin, Germany
[6] ACR ITR VIEnna, Vienna, Austria
[7] KFJ Spital, LBI ACR VIEnna, Vienna, Austria
[8] Merck KGaA, Global Clin Dev Unit, Darmstadt, Germany
[9] Univ Hosp Antwerpen, Edegem, Belgium
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：475 / 476
页数：2
相关论文
共 50 条
  • [1] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the phase II ADVANTAGE trial
    Gauler, T. C.
    Clement, P. M.
    Peyrade, F.
    Krauss, J.
    Mesia, R.
    Remenar, E.
    Keilholz, U.
    Delord, J. P.
    Schafhausen, P.
    Erfan, J.
    Brummendorf, T. H.
    Iglesias, L.
    Bethe, U.
    Hicking, C.
    Vermorken, J. B.
    ONKOLOGIE, 2012, 35 : 193 - 194
  • [2] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial
    Vermorken, Jan Baptist
    Peyrade, Frederic
    Krauss, Juergen
    Mesia, Ricard
    Remenar, Eva
    Gauler, Thomas C.
    Keilholz, Ulrich
    Delord, Jean-Pierre
    Schafhausen, Philippe
    Erfan, Jozsef
    Brummendorf, Tim H.
    Iglesias, Lara
    Bethe, Ullrich
    de La Bourdonnaye, Guillaume
    Clement, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Humblet, Y
    Vega-Villegas, E
    Mesia, R
    Awada, A
    Geoffrois, L
    Borel, C
    Hitt, R
    Amellal, N
    Bessa, EH
    Bourhis, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 491S - 491S
  • [4] Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)
    Vermorken, J. B.
    Peyrade, F.
    Krauss, J.
    Mesia, R.
    Remenar, E.
    Gauler, T. C.
    Keilholz, U.
    Delord, J. P.
    Schafhausen, P.
    Erfan, J.
    Bruemmendorf, T. H.
    Iglesias, L.
    Bethe, U.
    Hicking, C.
    Clement, P. M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 682 - 688
  • [5] Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
    J B Vermorken
    J Guigay
    R Mesia
    J M Trigo
    U Keilholz
    A Kerber
    U Bethe
    M Picard
    T H Brummendorf
    British Journal of Cancer, 2011, 104 : 1691 - 1696
  • [6] Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
    Vermorken, J. B.
    Guigay, J.
    Mesia, R.
    Trigo, J. M.
    Keilholz, U.
    Kerber, A.
    Bethe, U.
    Picard, M.
    Brummendorf, T. H.
    BRITISH JOURNAL OF CANCER, 2011, 104 (11) : 1691 - 1696
  • [7] Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Bourhis, Jean
    Rivera, Fernando
    Mesia, Ricard
    Awada, Ahmad
    Geoffrois, Lionel
    Borel, Christian
    Humblet, Yves
    Lopez-Pousa, Antonio
    Hitt, Ricardo
    Vega Villegas, M. Eugenia
    Duck, Lionel
    Rosine, Dominique
    Amellal, Nadia
    Schueler, Armin
    Harstrick, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2866 - 2872
  • [8] Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer
    Joseph I. Clark
    Joshua B. Greene
    Ann Lau Clark
    Jay S. Dalal
    Craig C. Hofmeister
    Medical Oncology, 2013, 30
  • [9] Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer
    Clark, Joseph I.
    Greene, Joshua B.
    Clark, Ann Lau
    Dalal, Jay S.
    Hofmeister, Craig C.
    MEDICAL ONCOLOGY, 2013, 30 (01)
  • [10] A RANDOMIZED, OPEN-LABEL, PHASE II STUDY OF AFATINIB VERSUS CETUXIMAB IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
    Seiwert, T. Y.
    Fayette, J.
    Cupissol, D.
    DelCampo, J. M.
    Clement, P. M.
    Tourani, J. M.
    Degardin, M.
    Blackman, A. S.
    Cong, J.
    Solca, F.
    Ehrnrooth, E.
    Cohen, E. E. W.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 35
12345